Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Momenta Pharmaceuticals Inc (MNTA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Momenta's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
52.48 0.00    0.00%
30/09 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US60877T1007 
CUSIP:  60877T100
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 52.46 - 52.53
Momenta 52.48 0.00 0.00%
IndustryBiotechnology
SectorHealthcare
Employees

118

Equity Type

ORD

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel therapeutics for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy; and M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity. The company’s biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. Momenta Pharmaceuticals, Inc. has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. Momenta Pharmaceuticals, Inc. is a subsidiary of Johnson & Johnson.

Contact Information

Phone 617 491 9700
Fax 617 621 0431

Top Executives

Name Age Since Title
Elizabeth Stoner 69 2007 Independent Director
Jose-Carlos Gutierrez-Ramos 57 2016 Independent Director
Donna R. Grogan 63 2019 Independent Director
Steven C. Gilman 67 2016 Independent Director
Georges Gemayel - 2016 Independent Director
Jane Barlow 59 2019 Independent Director
Ian D. Fier 53 2018 Chief Manufacturing and Program Officer
Alejandra V. Carvajal 46 2018 Chief Legal Officer, General Counsel and Secretary
Santiago Arroyo 60 2018 Chief Medical Officer
Anthony M. Manning 58 2018 Chief Scientific Officer
Agnieszka Cieplinska 43 2020 Chief Accounting Officer, Vice President - Finance, Corporate Controller
Jo-Ann Beltramello 52 2018 Chief Human Resources and Infrastructure Officer
Bruce L. Downey 72 2018 Independent Chairman of the Board
Craig A. Wheeler 59 2018 President, Chief Executive Officer, Director
Young Kwon 48 2020 Chief Financial and Business Officer
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MNTA Comments

Write your thoughts about Momenta Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
ray dauria
ray dauria Sep 02, 2020 1:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
📉
Red Or Green
Red Or Green Aug 19, 2020 12:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So tomorrow a big drop?
Joshua Carmichael
Joshua Carmichael Aug 19, 2020 12:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
no. JNJ acquired them for 6.5 mill. in a straight cash transaction.
Uri Baro
Uri Baro Aug 19, 2020 11:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what's has happened?
Justin Hall
Justin Hall Aug 19, 2020 11:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Acquired.
Jack Lee
Jack Lee Jun 30, 2020 9:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Drop a lot?
TRADERS INC
TRADERS INC Nov 10, 2019 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
157341834262121.jpg
Improving EPS and Revenues for MNTA. Nice looking up trend on the weekly, but must break through Resistance above closing price of $17 before i buy in. Looking at low 20's in the next few weeks if it breaks through.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email